Abstract
Ceftazidime (CAZ, SN401) was given by drip infusion to a total of 11 patients with intractable chronic respiratory infections, namely 6 patients who had not responded to other antibiotics and 5 patients with severe conditions, and the clinical efficacy and safety of the drug were evaluated.
1. The clinical efficacy was assessed as excellent in 3 cases, good in 4, fair in 3 and poor in 1, with the efficacy rate 63.6%.
2. In the cases of the intractable chronic respiratory infections caused by Pseudomonas aeruginosa, the treatment with a high dose of 2g twice daily, i. e. a total of 4 g per day, was found to be more effective than 2 g daily.
3. In the 5 cases of infections caused by P.aeruginosa, the causative organism became negative in 1 case, decreased in 2 cases and no change was observed in 2 cases. In the 3 cases of Klebsiella pneumoniae infections, the causative organism was eradicated in 2 cases, and no change was obtained in 1 case. The organism was decreased in the case of Enterobacter cloacae infection.
4. No adverse effect developed in any patient, and an abnormality in laboratory findings was observed in only 1 case as a slight increase in eosinophil.
